149 results on '"Morrow, Phuong Khanh"'
Search Results
2. Abstract 16908: CTX310: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces ANGPTL3 Protein and Triglyceride Levels in Non-Human Primates After a Single Dose
3. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
4. Exagamglogene Autotemcel for Severe Sickle Cell Disease
5. Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition
6. Elimination of Vaso-Occlusive Crises after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease
7. Transfusion Independence after Exagamglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia
8. Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients
9. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
10. A Randomized, Single-Blind Study Evaluating the Effect of a Bone Pain Education Video on Reported Bone Pain in Patients with Breast Cancer Receiving Chemotherapy and Pegfilgrastim
11. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer
12. An Executive’s View of Value of Platform Trials
13. Breast Cancer Survivorship Management
14. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim
15. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim
16. A review of relative dose intensity and survival in patients with metastatic solid tumors
17. Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials
18. Effect of Age and Race On Quality of Life in Young Breast Cancer Survivors
19. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe
20. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
21. Breast Cancer Survivorship Management
22. Targeting MCL-1 in hematologic malignancies: Rationale and progress
23. An Open-Label, Phase 2 Trial of RPI.4610 (Angiozyme) in the Treatment of Metastatic Breast Cancer
24. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model
25. A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma
26. Pregnancy After the Diagnosis of Breast Cancer
27. New Biological Agents in the Treatment of Advanced Non-Small Cell Lung Cancer
28. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
29. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
30. Management of breast cancer in the genome era
31. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim
32. Reply to Barroso-Sousa R et al.
33. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)
34. Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers
35. Exagamglogene Autotemcel for Severe Sickle Cell Disease
36. Nolan: A randomized, phase II study to estimate the effect of prophylactic naproxen (N) or loratadine (L) vs no intervention on bone pain in 600 patients (pts) with early-stage breast cancer receiving chemotherapy (chemo) and pegfilgrastim (PEG).
37. Evaluating the appropriateness of granulocyte colony-stimulating factor (G-CSF) use in patients (pts) receiving myelosuppressive chemotherapy by febrile neutropenia (FN) risk level.
38. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices
39. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
40. Abstract P6-10-01: Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN
41. Assessing patients’ risk of febrile neutropenia: is there a correlation between physician‐assessed risk and model‐predicted risk?
42. Oral Antimicrobial Drug Use during Chemotherapy in Medicare Enrollees with NHL
43. Translational Modeling to Identify Human Dosing of Filgrastim to Improve Overall Survival (OS) in Acute Radiation Syndrome (ARS)
44. Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”
45. Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL
46. Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers.
47. A multicenter observational study comparing physician-assessed febrile neutropenia (FN) risk and prediction-model severe neutropenia (SN) or FN risk in patients (pts) with nonmyeloid malignancies.
48. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received (neo)adjuvant chemotherapy in community oncology practices.
49. Survival outcomes of patients (pts) who received filgrastim (fil) or pegfilgrastim (peg) in clinical trials.
50. A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.